PMC:7784786 / 668-751 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"28","span":{"begin":48,"end":52},"obj":"Gene"},{"id":"35","span":{"begin":18,"end":28},"obj":"Chemical"}],"attributes":[{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Gene:3569"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:C000597346"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" access protocol. Itolizumab was able to reduce IL-6 concentrations in all the pati"}